Governors from Washington, Oregon, and California today announced the formation of the West Coast Health Alliance in the wake of drastic shakeups at the Centers for Disease Control and Prevention (CDC) last week and confusion over immunization recommendations, including new limits placed on who is eligible to receive COVID vaccines. 

"The CDC has become a political tool that increasingly peddles ideology instead of science, ideology that will lead to severe health consequences. California, Oregon, and Washington will not allow the people of our states to be put at risk," the governors said in a joint statement this morning. 

The alliance will "help ensure the public has access and credible information for confidence in vaccine safety and efficacy," according to the statement.

No info yet on COVID-19 vaccines

The alliance said they will be safeguarding scientific expertise by ensuring that public health policies in California, Oregon, and Washington are informed by trusted scientists, clinicians, and other public health leaders, per the press statement. 

Our communities deserve clear and transparent communication about vaccines—communication grounded in science, not ideology. 

Sejal Hathi, MD, MBA, director of the Oregon Health Authority, said, "Our communities deserve clear and transparent communication about vaccines—communication grounded in science, not ideology. Vaccines are among the most powerful tools in modern medicine; they have indisputably saved millions of lives."

It is unclear at this time if the alliance will distribute COVID-19 vaccines, which have been a feature of in-fighting at the CDC this summer. The press statement also did not address potential costs of COVID-19 vaccines for recipients who are not in the recommended use groups. 

"In the coming weeks, the Alliance will finalize shared principles to strengthen public confidence in vaccines and in public health," the statement said. "In a vacuum of clear, evidence-based vaccine guidance, manufacturers lack reliable information to plan production, health care providers struggle to provide consistent plans of care, and families face uncertainty about access and coverage."

Daily use of an interferon-alpha (IFN-α) nasal spray lowers the risk of COVID-19 infection in adults with cancer, a new randomized controlled trial finds.

For the multicenter study, published last week in Clinical Infectious Diseases, researchers at the University of Melbourne in Australia randomly assigned participants to receive daily IFN-α nasal spray (217 participants) or a saline placebo (216) from December 2020 to April 2023. Participants had solid-tumor or blood cancer with no history of COVID-19 infection.

Participants who developed influenza-like symptoms in the 90 days after randomization collected nasal swabs for polymerase chain reaction (PCR) testing for COVID-19, influenza A/B, respiratory syncytial virus, parainfluenza, adenovirus, seasonal coronavirus, picornavirus, and/or human metapneumovirus, or they had COVID-19 rapid antigen testing. 

Study visits occurred at 30, 60, and 90 days, at which time participants provided blood samples and completed a questionnaire. 

"Preventative measures, such as vaccination and monoclonal antibodies, have dramatically improved outcomes but many cancer populations experience breakthrough infections and have suboptimal vaccine responses," the authors wrote.

Lower rates in younger, female, vaccinated patients

The COVID-19 infection rate was lower in the IFN-α group than in placebo recipients (8.3% vs 14.4%), for a 40% reduced risk. The incidence of other viral respiratory infections was 5.1% in both groups, but the case numbers were too low to reach a conclusion about efficacy. 

There may be a role for short-term IFN-α nasal spray in addition to vaccination and monoclonal antibodies in preventing COVID-19.

In the 389-person per-protocol cohort, rates of COVID-19 infection in IFN-α and placebo recipients were 7.7% and 16.0%, indicating half the risk. Other respiratory virus incidence was 4.6% and 5.7% in the two groups, respectively. 

A subgroup analysis demonstrated lower COVID-19 incidence in IFN-α recipients younger than 65 years (relative risk [RR], 0.48), women (RR, .44), and vaccinated recipients (RR, 0.50) but no difference by cancer type, disease severity, hospitalization, or death. IFN-α was well tolerated.

The researchers noted that IFN-α has antiviral, antimicrobial, antiproliferative, and immunomodulatory effects. "There may be a role for short-term IFN-α nasal spray in addition to vaccination and monoclonal antibodies in preventing COVID-19," they wrote.

CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) announced today that it is awarding $1 million to biotechnology company Zeteo Tech to advance work on a noninvasive diagnostic test that can diagnose lower respiratory tract infections (LRTIs) from exhaled breath.

The funding will enable Maryland-based Zeteo Tech to execute a workplan for BreathBiomics, a noninvasive diagnostic platform that employs a matrix-assisted laser desorption and ionization mass spectrometry (MALDI-MS) assay to analyze breath aerosol to distinguish between viral and bacterial infections, differentiate active infection from colonization, and assess antibiotic susceptibility. 

CARB-X says the company will use the money to explore the use of breath samples from children as an alternative to bronchoalveolar lavage or sputum collection, the methods typically used to collect samples from children with suspected LRTIs. The hope is that a rapid, less invasive diagnostic test for LRTIs like pneumonia, which claims the lives of 700,000 children under 5 years annually, could expedite diagnosis, reduce unnecessary antibiotic treatment, and guide more effective treatment for drug-resistant LRTIs.

Focus on novel diagnostics for LRTIs

The award is the latest from CARB-X's March 2024 funding round, which is focused on four distinct product themes, including proof-of-concept for tests using novel sample types to diagnose LRTIs.

"Diagnosing lower respiratory tract infections rapidly and accurately remains a significant clinical challenge, particularly in critical care settings," CARB-X research and development (R&D) chief Erin Duffy, PhD, said in a press release. "We look forward to seeing how Zeteo's technology performs in early-stage development and what insights it may bring to inform improved patient outcomes."

Since its inception in 2016, CARB-X has supported 118 early-stage R&D projects designed to prevent, treat, and diagnose antibiotic resistant infections. Twenty-two of those projects have advanced into or completed clinical trials.